Kidney Cancer
The management of metastatic renal cell carcinoma (RCC) has evolved rapidly in recent years with several immunotherapy-based combinations of strategies approved as first-line therapies. Targeted strategies, including systemic antiangiogenesis agents and immune checkpoint blockade, form the basis of a therapeutic approach. With rising rates of recurrence after first-line treatment, it is increasingly important to not only adopt a personalized treatment plan with minimal adverse events but also develop predictive biomarkers for response. This review discusses currently available first-line and second-line therapies in RCC and their pivotal data, with specific focus on ongoing clinical trials in the adjuvant setting, including those involving novel agents.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Nivedita Chowdhury, Charles G. Drake Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology